Clinical practice utilizes the status of estrogen receptor (ER), progesterone receptor (PR), and HER2 hormone receptors to categorize breast cancer, enabling the optimization of personalized therapeutic strategies for each patient [9,10]. This evidence concerns the gene ERBB2 and breast cancer.